VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | EMERALD-1 trial in HCC

Bruno Sangro, MD, PhD, of Clinica Universidad de Navarra, Navarra, Spain, discusses results from the Phase III EMERALD-1 study (NCT03778957) which aimed to characterize transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter